Pharmacosmos launches iron deficiency drug in Japan
The Danish pharmaceutical company has been granted national reimbursement in Japan for its main asset, which is now being launched in the country.
by stine løcke nielsen, translated by daniel pedersen
Pharmacosmos has reason to celebrate after winning national reimbursement in Japan for iron deficiency treatment Monofer (ferric derisomaltose).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos wins Chinese reimbursement deal
For subscribers
Pharmacosmos tight-lipped on competitor's Chinese market nod
For subscribers
.jpg&w=384&q=75)
